Patient-funded biotech in $100 mln funding deal for DMD drug

Jan 8 (Reuters) - Akashi Therapeutics Inc, a U.S.-based biotech funded by DMD patient foundations, said it would get up to $100 million under a partnership with Germany's Grunenthal SA for developing a drug for the muscle-wasting disorder.